KRAS-targeting vaccine prompts immune responses in pancreatic cancer patients

An investigational vaccine helped the immune system recognize and respond to mutations that drive most pancreatic cancers, according to results from a randomized phase 2 clinical trial led by Mayo Clinic researchers.

Read Original Copy